Cargando…

Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs

PURPOSE: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections. METHODS: A prospective interventional case series study recruited patients from a single center diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Walid S., Eldaly, Zeiad H., Saleh, Mohamed G., Rateb, Mahmoud F., Aldoghaimy, Ahmed H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Ophthalmological Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462479/
https://www.ncbi.nlm.nih.gov/pubmed/30977321
http://dx.doi.org/10.3341/kjo.2018.0037
_version_ 1783410624123895808
author Ibrahim, Walid S.
Eldaly, Zeiad H.
Saleh, Mohamed G.
Rateb, Mahmoud F.
Aldoghaimy, Ahmed H.
author_facet Ibrahim, Walid S.
Eldaly, Zeiad H.
Saleh, Mohamed G.
Rateb, Mahmoud F.
Aldoghaimy, Ahmed H.
author_sort Ibrahim, Walid S.
collection PubMed
description PURPOSE: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections. METHODS: A prospective interventional case series study recruited patients from a single center diagnosed with DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of aflibercept were performed. The primary outcome measure was mean change in visual acuity after switching to aflibercept. RESULTS: Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution (logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ± 0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57 ± 107.09 µm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03, 328.24 ± 81.98, and 313.71 ± 85.79 µm, respectively). Both visual improvement and mean change in retinal thickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMAR but were not significant in patients with best-corrected visual acuity more than 1.0 logMAR. CONCLUSIONS: Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGF injections provided acceptable short-term visual and retinal architectural improvement.
format Online
Article
Text
id pubmed-6462479
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Ophthalmological Society
record_format MEDLINE/PubMed
spelling pubmed-64624792019-04-21 Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs Ibrahim, Walid S. Eldaly, Zeiad H. Saleh, Mohamed G. Rateb, Mahmoud F. Aldoghaimy, Ahmed H. Korean J Ophthalmol Original Article PURPOSE: To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections. METHODS: A prospective interventional case series study recruited patients from a single center diagnosed with DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of aflibercept were performed. The primary outcome measure was mean change in visual acuity after switching to aflibercept. RESULTS: Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution (logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ± 0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57 ± 107.09 µm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03, 328.24 ± 81.98, and 313.71 ± 85.79 µm, respectively). Both visual improvement and mean change in retinal thickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMAR but were not significant in patients with best-corrected visual acuity more than 1.0 logMAR. CONCLUSIONS: Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGF injections provided acceptable short-term visual and retinal architectural improvement. The Korean Ophthalmological Society 2019-04 2019-04-08 /pmc/articles/PMC6462479/ /pubmed/30977321 http://dx.doi.org/10.3341/kjo.2018.0037 Text en © 2019 The Korean Ophthalmological Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ibrahim, Walid S.
Eldaly, Zeiad H.
Saleh, Mohamed G.
Rateb, Mahmoud F.
Aldoghaimy, Ahmed H.
Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
title Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
title_full Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
title_fullStr Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
title_full_unstemmed Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
title_short Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
title_sort switching to aflibercept in diabetic macular edema after unsatisfactory response to other anti-vascular endothelial growth factor drugs
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462479/
https://www.ncbi.nlm.nih.gov/pubmed/30977321
http://dx.doi.org/10.3341/kjo.2018.0037
work_keys_str_mv AT ibrahimwalids switchingtoafliberceptindiabeticmacularedemaafterunsatisfactoryresponsetootherantivascularendothelialgrowthfactordrugs
AT eldalyzeiadh switchingtoafliberceptindiabeticmacularedemaafterunsatisfactoryresponsetootherantivascularendothelialgrowthfactordrugs
AT salehmohamedg switchingtoafliberceptindiabeticmacularedemaafterunsatisfactoryresponsetootherantivascularendothelialgrowthfactordrugs
AT ratebmahmoudf switchingtoafliberceptindiabeticmacularedemaafterunsatisfactoryresponsetootherantivascularendothelialgrowthfactordrugs
AT aldoghaimyahmedh switchingtoafliberceptindiabeticmacularedemaafterunsatisfactoryresponsetootherantivascularendothelialgrowthfactordrugs